These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 27890418)
1. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418 [TBL] [Abstract][Full Text] [Related]
2. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
3. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus. Arhin FF; Sarmiento I; Parr TR; Moeck G Int J Antimicrob Agents; 2012 Feb; 39(2):159-62. PubMed ID: 22070858 [TBL] [Abstract][Full Text] [Related]
4. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. Arhin FF; Sarmiento I; Moeck G Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505 [TBL] [Abstract][Full Text] [Related]
5. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Smith JR; Yim J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159 [TBL] [Abstract][Full Text] [Related]
6. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Vidaillac C; Parra-Ruiz J; Rybak MJ Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937 [TBL] [Abstract][Full Text] [Related]
7. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. LaPlante KL; Rybak MJ Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842 [TBL] [Abstract][Full Text] [Related]
8. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Belley A; Lalonde Seguin D; Arhin F; Moeck G Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327 [TBL] [Abstract][Full Text] [Related]
9. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Mortin LI; Li T; Van Praagh AD; Zhang S; Zhang XX; Alder JD Antimicrob Agents Chemother; 2007 May; 51(5):1787-94. PubMed ID: 17307984 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Saravolatz LD; Pawlak J; Johnson LB Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881 [TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis. Knaack D; Idelevich EA; Schleimer N; Molinaro S; Kriegeskorte A; Peters G; Becker K Diagn Microbiol Infect Dis; 2019 Apr; 93(4):362-368. PubMed ID: 30554844 [TBL] [Abstract][Full Text] [Related]
15. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
18. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Huang YT; Liao CH; Teng LJ; Hsueh PR Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671 [TBL] [Abstract][Full Text] [Related]